Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
about
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionInfluence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.Novel agents for the treatment of resistant Gram-positive infections.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Oritavancin: a new avenue for resistant Gram-positive bacteria.Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.Oritavancin--an investigational glycopeptide antibiotic.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Vancomycin resistance: are there better glycopeptides coming?Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.
P2860
Q34937444-B821B8D1-5425-46D7-819A-A36ED68AAE08Q35014464-6D316E26-CBCD-4C22-AE57-A0ACC205A662Q35056042-18A05975-7758-453E-BDEB-C64D6BC60C66Q35637071-5E63B0C1-A815-4E97-96DE-D841A88F7613Q36162339-8B52D0EC-9F1A-4A76-87FA-D150A027116BQ36283731-85364BCD-68B5-40E7-9664-B10677C70E5CQ36426011-489CAABA-A596-4AEB-83B3-61AD863E11C5Q36718474-B46D7FBC-56EC-4974-B981-BA5EDA3E8133Q36847287-BF339CD3-AF4E-458F-A0FE-BC94ECB08238Q37071199-755F3500-B80C-4A4A-91F4-607575F6C597Q37174100-AAF9D67D-9407-4E35-9DD1-9B01F7F14059Q37340562-6AB76749-B282-455D-960C-566BEEA901E8Q42530056-CD61C1DB-649A-4CDC-96D6-27348AA9CE11Q46255695-B5442A32-0A8E-4E58-BA49-31BDB81D5221Q52595189-45BC165F-04C7-4AB4-956D-F6678EB3D18E
P2860
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Activities of LY333328 and van ...... harmacodynamic infection model
@ast
Activities of LY333328 and van ...... harmacodynamic infection model
@en
type
label
Activities of LY333328 and van ...... harmacodynamic infection model
@ast
Activities of LY333328 and van ...... harmacodynamic infection model
@en
prefLabel
Activities of LY333328 and van ...... harmacodynamic infection model
@ast
Activities of LY333328 and van ...... harmacodynamic infection model
@en
P2093
P2860
P1476
Activities of LY333328 and van ...... harmacodynamic infection model
@en
P2093
E Hershberger
J R Aeschlimann
P2860
P304
P356
10.1128/AAC.44.11.2991-2998.2000
P407
P577
2000-11-01T00:00:00Z